Saturday 17 October 2026
Export LITS’s income statement to Excel — free account
Lite Strategy, Inc.
LITS Healthcare Biotechnology
Lite Strategy, Inc.’s revenue for fiscal 2024 (year ended June 2024) was $65.3 million, up 33.8% from fiscal 2023. In the quarter to June 2026, EPS fell 11.0% and free cash flow grew 179.3%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
1.14
0.06
−5.00%
Follow LITS
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(16.88%) | (76.38%) | (159.26%) | (243.02%) | |
| (16.41%) | (73.98%) | (154.82%) | (233.37%) | ||
ROIC |
(7.86%) | (33.57%) | (73.66%) | (115.85%) | |
Return on Tangible Assets |
(95.14%) | (404.06%) | (606.80%) | (1,402.80%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(0.47) | (0.33) | (0.29) | (3.01) | |
Free Cash Flow |
(13.90) | (12.16) | (10.42) | (104.08) | |
Capital Expenditures |
— | — | — | (94.96) | |
| Other line items | |||||
Cash ROIC |
(11.36%) | (13.43%) | (16.18%) | (219.91%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
1.20 | 0.31 | 0.17 | 0.13 | |
Capex/Depreciation |
— | — | — | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.47) | (0.33) | (0.29) | (0.26) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (2.75) | |
Capex to Sales |
— | — | — | 0.00 |
Columns are period end dates · fundamentals updated 30 Sep 2026